Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126145 | 1.00 | SCN9A (1.00) | SCN9A | |
| SCHEMBL14932568 | 1.00 | SCN9A (1.00) | SCN9A | |
| SCHEMBL14920149 | 0.88 | SCN9A (0.84) | SCN9A | |
| SCHEMBL14920134 | 0.88 | SCN9A (1.00) | SCN9A | |
| SCHEMBL14919812 | 0.88 | SCN9A (1.00) | SCN9A | |
| SCHEMBL14919752 | 0.88 | SCN9A (1.00) | SCN9A | |
| SCHEMBL15272268 | 0.82 | SCN9A (0.83) | SCN9A | |
| SCHEMBL787413 | 0.82 | SCN9A (1.00) | SCN9A | |
| SCHEMBL29421401 | 0.82 | SCN9A (1.00) | SCN9A | |
| SCHEMBL787414 | 0.82 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-25 | — | — | US | claimed |
| WO-2013064883-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | claimed |
| US-9624194-B2 | Heteroaryl compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160052911-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-02-25 | — | — | US | disclosed |
| US-9181185-B2 | Heteroaryl compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2013064883-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, SCN1A | SCN9A 16/4885 |
| US-20160052911-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, SCN1A | SCN9A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.